People taking GLP-1 weight loss drugs like Ozempic started moving less
Key takeaways
- The finding may come as a surprise because many people assume that shedding excess weight naturally makes it easier to move more.
- The medications studied belong to a class known as glucagon-like peptide-1 (GLP-1) receptor agonists.
- While these drugs can be highly effective for weight loss, they reduce more than just body fat.
Why this matters: new research or scientific developments with potential real-world impact.
People with obesity who lost weight while taking popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound became significantly less physically active, according to research presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois.
The finding may come as a surprise because many people assume that shedding excess weight naturally makes it easier to move more. However, researchers found the opposite trend among people taking these medications.
The medications studied belong to a class known as glucagon-like peptide-1 (GLP-1) receptor agonists. This group includes semaglutide (Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), liraglutide, and dulaglutide.